The KCNK17 antibody targets the KCNK17 protein, a member of the two-pore domain potassium (K2P) channel family (also known as TASK-4). KCNK17 channels regulate cellular excitability by mediating background potassium currents, contributing to resting membrane potential and action potential repolarization. Structurally, K2P channels feature two pore-forming domains and four transmembrane segments, enabling leak potassium conductance. KCNK17 is expressed in various tissues, including the brain, heart, and endocrine organs, and is implicated in physiological processes such as hormone secretion, apoptosis, and neuronal signaling. Dysregulation of KCNK17 has been linked to diseases like cancer, neurological disorders, and cardiovascular conditions. Antibodies against KCNK17 are essential tools for studying its expression, localization, and functional roles. They are typically developed using recombinant protein fragments or synthetic peptides as immunogens and validated via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Specificity is confirmed using knockout controls or siRNA-mediated knockdown. Research applications include exploring KCNK17's involvement in tumor progression (e.g., glioblastoma, breast cancer) or its modulation by pharmacological agents. These antibodies also aid in biomarker discovery and therapeutic target validation.